Trial Profile
Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real world clinical practice in Japan.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Aug 2015 New trial record